Hong Kong Journal of Nephrology
Volume 13, Issue 1 , Pages 19-26, April 2011

Novel Drug Treatment for Diabetic Nephropathy

  • Amitabh Dash

      Affiliations

    • Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    • Corresponding Author InformationCorrespondence to: Dr. Amitabh Dash, E-13, Kalkaji, New Delhi 110019, India
    • ,
  • Rituparna Maiti

      Affiliations

    • Department of Pharmacology, Prathima Institute of Medical Sciences, Karimnagar, Andhra Pradesh, India
    • ,
  • Tejaswi Kumar Akantappa Bandakkanavar

      Affiliations

    • Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    • ,
  • Bajrang Lal Pandey

      Affiliations

    • Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

Article Outline

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. In addition to the renin pathway, certain bioactive molecules are involved in its pathogenesis. Strategies to interrupt pathophysiological pathways are on the horizon. Aliskiren, a renin inhibitor, blocks the first step in the renin pathway. Protein kinase C overexpression is blocked by ruboxistaurin. Pentoxifylline and m-TOR inhibitors are anti-inflammatory agents in the pathogenesis of diabetic nephropathy. Inhibitors of advanced glycation, oxidative stress, and plasminogen activator inhibitor-1 have proved useful in animal models of diabetic nephropathy. Avosentan, an endothelin antagonist, decreases urinary albumin. Such targeted therapies have opened up avenues for researchers to develop agents that can halt and may even reverse the progression of diabetic nephropathy.

Key words:  diabetes mellitus , nephropathy , novel drugs

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Guilbert JJ . The World Health Report 2006: Working Together with Health . Educ Health (Abingdon) . 2006;19:385–387
  2. Wu AY , Kong NC , De Leon FA , et al.   An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the Micro-Albuminuria Prevalence (MAP) study . Diabetologia . 2005;48:17–26
  3. Dalla Vestra M , A Saller , E Bortoloso , et al.   Structural involvement in type 1 and type 2 diabetic nephropathy . Diabetes Metab . 2000;26(Suppl 4):8–14
  4. Mogensen CE . Renal function changes in diabetes . Diabetes . 1976;25(Suppl):872–879
  5. Maiti R , Agrawal NK . Atherosclerosis in diabetes mellitus: role of inflammation . Indian J Med Sci . 2007;61:292–306
  6. Calcutt NA , Cooper ME , Kern TS , et al.   Therapies for hyperglycaemiainduced diabetic complications: from animal models to clinical trials . Nat Rev Drug Discov . 2009;8:417–429
  7. Ruggenenti P , Cravedi P , Remuzzi G . The RAAS in the pathogenesis and treatment of diabetic nephropathy . Nat Rev Nephrol . 2010;6:319–330
  8. V D'agati , AM Schmidt . RAGE and the pathogenesis of chronic kidney disease . Nat Rev Nephrol . 2010;6:352–360
  9. Decleves AE , Sharma K . New pharmacological treatments for improving renal outcomes in diabetes . Nat Rev Nephrol . 2010;6:371–380
  10. Wu D , Peng F , Zhang B , et al.   PKC-β1 mediates glucose-induced Akt activation and TGF-β1 upregulation in mesangial cells . J Am Soc Nephrol . 2009;20:554–566
  11. Durvasula RV , Shankland SJ . Activation of a local renin angiotensin system in podocytes by glucose . Am J Physiol Renal Physiol . 2008;294:F830–F839
  12. Lee SH , Yoo TH , Nam BY , et al.   Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions . Am J Physiol Renal Physiol . 2009;297:F1381–F1390
  13. Miceli I , Burt D , Tarabra E , et al.   Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone . Am J Physiol Renal Physiol . 2010;298:F381–F390
  14. Jauregui A , Mintz DH , Mundel P , et al.   Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria . Curr Opin Nephrol Hypertens . 2009;18:539–545
  15. Welsh GI , Coward RJ . Podocytes, glucose and insulin . Curr Opin Nephrol Hypertens . 2010;19:379–384
  16. Welsh GI , Hale LJ , Eremina V , et al.   Insulin signaling to the glomerular podocyte is critical for normal kidney function . Cell Metab . 2010;12:329–340
  17. Siebel AL , Fernandez AZ , A El-Osta . Glycemic memory associated epigenetic changes . Biochem Pharmacol . 2010;80:1853–1859
  18. Tonna S , El-Osta A , Cooper ME , et al.   Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms . Nat Rev Nephrol . 2010;6:332–341
  19. Villeneuve LM , Natarajan R . The role of epigenetics in the pathology of diabetic complications . Am J Physiol Renal Physiol . 2010;299:F14–F25
  20. Azizi M , Ménard J , Bissery A , et al.   Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodiumreplete normotensive indivisuals . Clin J Am Soc Nephrol . 2007;2:947–955
  21. Kelly DJ , Zhang Y , Moe G , et al.   Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats . Diabetologia . 2007;50:2398–2404
  22. Parving HH , Persson F , Lewis JB , et al.   Aliskiren combined with losartan in type 2 diabetes and nephropathy . N Engl J Med . 2008;358:2433–2446
  23. Feldman DL , Jin L , Xuan H , et al.   Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats . Hypertension . 2008;52:130–136
  24. Parving HH , Brenner BM , McMurray JJ , et al.   Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design . Nephrol Dial Transplant . 2009;24:1663–1671
  25. Gaddam KK , Oparil S . Renin inhibition: should it supplant ACE inhibitors and ARBs in high risk patients? . Curr Opin Nephrol Hypertens . 2008;17:484–490
  26. Gilbert RE , Kim SA , Tuttle KR , et al.   Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes . Diabetes Care . 2007;30:995–996
  27. Kelly DJ , Zhang Y , Hepper C , et al.   Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension . Diabetes . 2003;52:512–518
  28. Kelly DJ , Buck D , Cox AJ , et al.   Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy . Am J Physiol Renal Physiol . 2007;293:F565–F574
  29. Kelly DJ , Chanty A , Gow RM , et al.   Protein kinase C inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy . J Am Soc Nephrol . 2005;16:1654–1660
  30. Tuttle KR , Bakris GL , Toto RD , et al.   The effect of ruboxistaurin on nephropathy in type 2 diabetes . Diabetes Care . 2005;28:2686–2690
  31. Lieberthal W , Levine JS . The role of the mammalian target of rapamycin (mTOR) in renal disease . J Am Soc Nephrol . 2009;20:2493–2502
  32. Sakaguchi M , Isono M , Isshiki K , et al.   Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice . Biochem Biophys Res Commun . 2006;340:296–301
  33. Mori H , Inoki K , Masutani K , et al.   The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential . Biochem Biophys Res Commun . 2009;384:471–475
  34. Yang Y , Wang J , Qin L , et al.   Rapamycin prevents early steps of the development of diabetic nephropathy in rats . Am J Nephrol . 2007;27:495–502
  35. Wittmann S , Daniel C , Stief A , et al.   Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in rats . Transplantation . 2009;87:1290–1299
  36. Navarro JF , Milena FJ , Mora C , et al.   Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensinconverting enzyme inhibition and pentoxifylline administration . Am J Nephrol . 2006;26:562–570
  37. BB McCormick , A Sydor , A Akbari , et al.   The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis . Am J Kidney Dis . 2008;52:454–463
  38. R Leyva-Jiménez , AR Rodríguez-Orozco , LE Ortega-Pierres , et al.   Effect of pentoxifylline on the evolution of diabetic nephropathy . Med Clin (Barc) . 2009;132:772–778
  39. Navarro-González JF, Muros M, Mora-Fernández C, et al. Pentoxifylline for Renoprotection in Diabetic Nephropathy: the PREDIAN study-rationale and basal results. J Diabetes Complications 2010 Dec 6. [Epub ahead of print]
  40. T Dan , van Ypersele de Strihou C , T Miyata . Advanced glycation end products inhibitor . In: Studies on Renal Disorders: Oxidative Stress in Applied Basic Research and Clinical Practice, Part 3 . New York: Springer; 2011;p. 389–406
  41. Izuhara Y , Sada T , Yanagisawa H , et al.   A novel sartan derivative with very low angiotensin II type I receptor affinity protects the eye in type 2 diabetic rats . Arterioscler Thromb Vasc Biol . 2008;8:1767–1773
  42. Voziyan PA , Hudson BG . Pyridoxamine: the many virtues of a Maillard reaction inhibitor . Ann N Y Acad Sci . 2005;1043:807–816
  43. Murakoshi M , Tanimoto M , Gohda T , et al.   Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice . Diabetes Res Clin Pract . 2009;83:183–189
  44. Waanders F , van den Berg E , Nagai R , et al.   Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats . Nephrol Dial Transplant . 2008;23:518–524
  45. Williams ME , Bolton WK , Khalifah RG , et al.   Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy . Am J Nephrol . 2007;27:605–614
  46. Balakumar P , Rohilla A , Krishan P , et al.   The multifaceted therapeutic potential of benfotiamine . Pharmacol Res . 2010;61:482–488
  47. Stirban A , Negrean M , Stratmann B , et al.   Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes . Diabetes Care . 2006;29:2064–2071
  48. Marchetti V , Menghini R , Rizza S , et al.   Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling . Diabetes . 2006;55:2231–2237
  49. Alkhalaf A , Klooster A , van Oeveren W , et al.   A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy . Diabetes Care . 2010;33:1598–1601
  50. Coughlan MT , Forbes JM , Cooper ME . Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes . Kidney Int Suppl . 2007;106:S54–S60
  51. Dhar A , Desai KM , Wu L . Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats . Br J Pharmacol . 2010;159:166–175
  52. Peppa M , Brem H , Cai W , et al.   Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711) . Am J Nephrol . 2006;26:430–436
  53. Yamagishi S , Nakamura K , Matsui T , et al.   Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders . Med Hypotheses . 2007;69:666–668
  54. Miyazaki T , Aoyama I , Ise M , et al.   An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys . Nephrol Dial Transplant . 2000;15:1773–1781
  55. Ueda S , Yamagishi S , Takeuchi M , et al.   Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure . Mol Med . 2006;12:180–184
  56. Nicholas SB , Aguiniga E , Ren Y , et al.   Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy . Kidney Int . 2005;67:1297–1307
  57. Rerolle JP , Hertig A , Nguyen G , et al.   Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis . Kidney Int . 2000;58:1841–1850
  58. Izuhara Y , Takahashi S , Nangaku M , et al.   Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on anticoagulation and anti-fibrosis . Arterioscler Thromb Vasc Biol . 2008;28:672–677
  59. Izuhara Y , Yamaoka N , Kodama H , et al.   A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates . J Cerebral Blood Flow Metab . 2010;30:904–912
  60. Huang Y , Haraguchi M , Lawrence DA , et al.   A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis . J Clin Invest . 2003;112:379–388
  61. Miyata T , van Ypersele de Strihou C . Translation of basic science into clinical medicine: novel targets for diabetic nephropathy . Nephrol Dial Transplant . 2009;24:1373–1377
  62. Blouza S , Dakhli S , Abid H , et al.   Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy . J Nephrol . 2010;23:415–424
  63. Weiss R , Niecestro R , Raz I . The role of sulodexide in the treatment of diabetic nephropathy . Drugs . 2007;67:2681–2696
  64. Gambaro G , Kinalska I , Oksa A , et al.   Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial . J Am Soc Nephrol . 2002;13:1615–1625
  65. Burney BO , Kalaitzidis RG , Bakris GL . Novel therapies of diabetic nephropathy . Curr Opin Nephrol Hypertens . 2009;18:107–111
  66. Sharma K , Ziyadeh FN , Alzahabi B , et al.   Increased renal production of transforming growth factor-beta1 in patients with type II diabetes . Diabetes . 1997;46:854–859
  67. T Yamamoto , T Nakamura , NA Noble , et al.   Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy . Proc Natl Acad Sci USA . 1993;90:1814–1818
  68. Ramachandra Rao SP , Y Zhu , T Ravasi , et al.   Pirfenidone is reno-protective in diabetic kidney disease . J Am Soc Nephrol . 2009;20:1765–1775
  69. Mann JF , Green D , Jamerson K , et al.   Avosentan for overt diabetic nephropathy . J Am Soc Nephrol . 2010;21:527–535
  70. Sarafidis PA , Lasaridis AN . Diabetic nephropathy: endothelin antagonism for diabetic nephropathy . Nat Rev Nephrol . 2010;6:447–449
  71. Wenzel RR , Littke T , Kuranoff S , et al.   Avosentan reduces albumin excretion in diabetics with macroalbuminuria . J Am Soc Nephrol . 2009;20:655–664

PII: S1561-5413(11)60003-3

doi:10.1016/S1561-5413(11)60003-3

Hong Kong Journal of Nephrology
Volume 13, Issue 1 , Pages 19-26, April 2011

Article Tools